Our Company
Xanamem^®
Clinical Trials
Investor Centre
News
Contact Us

BACK TO NEWS

Lucy Lyon • 08 Jun 2023

Edison Investment Research update
Refining the upcoming XanaMIA Phase 2b study

Enjoyed this read?

Stay up to date with our latest research.

Related articles

Corporate Presentations

Webcast Video Recording: Actinogen updated Depression Trial results and implications presentation

Actinogen • August 30, 2024

Press Releases and Media

Actinogen announces further positive results on depression in the XanCIDD phase 2a trial

PR Newswire • August 26, 2024

Corporate Presentations

Webcast Video Recording: Actinogen XanaCIDD topline results presentation

Actinogen • August 12, 2024

Our Company
Xanamem^®

Clinical Trials

Investors
News
Contact Us
Target Market Determination

Copyright © 2024 Actinogen